Next report date
≈
August 6
Report period
Q2 2025
EPS estimate
12.19 MXN
Revenue estimate
83.43 B MXN
−23.27 MXN
−34.17 B MXN
344.22 B MXN
1.15 B
About TEVA
Sector
Industry
CEO
Richard Francis
Website
Headquarters
Tel Aviv
Founded
1901
FIGI
BBG001KHJPJ1
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
−21%
−14%
−7%
0%
7%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−30.00 B
0.00
30.00 B
60.00 B
90.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
20.00 B
40.00 B
60.00 B
80.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
20.00 B
40.00 B
60.00 B
80.00 B
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
100.00 B
200.00 B
300.00 B
400.00 B
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
TFAC
TEVA P.FI.NL III 16/46Yield to maturity
8.04%
Maturity date
Oct 1, 2046
TEVA.GJ
Teva Pharmaceutical Finance Co. LLC 0.25% 01-FEB-2026Yield to maturity
7.69%
Maturity date
Feb 1, 2026
TEVA4608603
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028Yield to maturity
6.96%
Maturity date
Mar 1, 2028
US88163VAD1
TEVA PHARM.FIN. 2036Yield to maturity
6.17%
Maturity date
Feb 1, 2036
TEVA6082388
Teva Pharmaceutical Finance Netherlands III BV 6.0% 01-DEC-2032Yield to maturity
5.83%
Maturity date
Dec 1, 2032
TFAB
TEVA P.FI.NL III 16/26Yield to maturity
5.72%
Maturity date
Oct 1, 2026
TEVA5549924
Teva Pharmaceutical Finance Netherlands III BV 8.125% 15-SEP-2031Yield to maturity
5.68%
Maturity date
Sep 15, 2031
TEVA5295244
Teva Pharmaceutical Finance Netherlands III BV 4.75% 09-MAY-2027Yield to maturity
5.56%
Maturity date
May 9, 2027
TEVA4608604
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028Yield to maturity
5.54%
Maturity date
Mar 1, 2028
TEVA6082389
Teva Pharmaceutical Finance Netherlands IV BV 5.75% 01-DEC-2030Yield to maturity
5.48%
Maturity date
Dec 1, 2030
TEVA5295245
Teva Pharmaceutical Finance Netherlands III BV 5.125% 09-MAY-2029Yield to maturity
5.41%
Maturity date
May 9, 2029
See all TEVA/N bonds